Platelet GP IIIa polymorphism HPA-1 (PlA) protects against subarachnoid hemorrhage

25Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background and Purpose - Few genetic modifications have been identified to be associated with subarachnoid hemorrhage (SAH), most of them playing a role in the formation or size of aneurysms. Methods - We evaluated the role of common and functional polymorphisms affecting the main platelet adhesive glycoproteins (GP) (GPIIIa: HPA-1; GPIa: HPA-5 and C807T; GPIbα: HPA-2 and VNTR) in the risk for development of the disease and in the severity of the onset. The study was performed in 103 patients with SAH, 103 matched controls, and 473 subjects from the general population. Results - The HPA-1b (PlA2) allele significantly protected against SAH (OR, 0.48; 95% CI, 0.24 to 0.96; P=0.037). Interestingly, patients carrying this allele displayed larger aneurysms, but the extension of their hemorrhage and the clinical grade at presentation was significantly lower when compared with patients HPA-1 a/a (11.9±2.8 mm versus 8.8±2.2 mm, P=0.0001. Fisher grade ≤2: 68.4% versus 20%; P=0.0001; Hunt and Hess score

Cite

CITATION STYLE

APA

Iniesta, J. A., González-Conejero, R., Piqueras, C., Vicente, V., & Corral, J. (2004). Platelet GP IIIa polymorphism HPA-1 (PlA) protects against subarachnoid hemorrhage. Stroke, 35(10), 2282–2286. https://doi.org/10.1161/01.STR.0000141978.33388.eb

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free